Ondine Biomedical Inc (OBI) - Cash Flow Conversion Efficiency

Latest as of December 2025: -3.853x

Based on the latest financial reports, Ondine Biomedical Inc (OBI) has a cash flow conversion efficiency ratio of -3.853x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-13.44 Million ≈ $-1.64K USD) by net assets (GBX3.49 Million ≈ $424.53 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Ondine Biomedical Inc to measure how much of total assets are equity-financed.

Ondine Biomedical Inc - Cash Flow Conversion Efficiency Trend (2001–2025)

This chart illustrates how Ondine Biomedical Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow reinvestment rate of Ondine Biomedical Inc to assess the company's total reinvestment commitment from operating cash flow.

Ondine Biomedical Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Ondine Biomedical Inc ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Network Media Group Inc V:NTE	0.082x
Portofino Resources Inc V:POR	-0.013x
FINEQIA INTERN. INC. O.N. F:FNQA	0.125x
Eurasia Mining LSE:EUA	0.032x
Yolo SA WAR:YOL	0.005x
LABOCANNA S.A. ZY-10 F:9Y2	-0.043x
Eco Animal Health Group Plc LSE:EAH	-0.011x
PDG Realty S.A. Empreendimentos e Participações SA:PDGR3	0.000x

Annual Cash Flow Conversion Efficiency for Ondine Biomedical Inc (2001–2025)

The table below shows the annual cash flow conversion efficiency of Ondine Biomedical Inc from 2001 to 2025. For the full company profile with market capitalisation and key ratios, see OBI market cap overview.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	GBX3.49 Million ≈ $424.53	GBX-23.90 Million ≈ $-2.91K	-6.851x	-204.17%
2024-12-31	GBX6.88 Million ≈ $836.73	GBX-15.49 Million ≈ $-1.88K	-2.252x	+65.60%
2023-12-31	GBX2.08 Million ≈ $253.68	GBX-13.65 Million ≈ $-1.66K	-6.548x	-366.49%
2022-12-31	GBX11.64 Million ≈ $1.42K	GBX-16.34 Million ≈ $-1.99K	-1.404x	-231.98%
2021-12-31	GBX29.66 Million ≈ $3.61K	GBX-12.54 Million ≈ $-1.53K	-0.423x	-325.93%
2020-12-31	GBX-33.83 Million ≈ $-4.12K	GBX-6.33 Million ≈ $-770.30	0.187x	-35.38%
2019-12-31	GBX-26.07 Million ≈ $-3.17K	GBX-7.55 Million ≈ $-918.74	0.290x	-48.60%
2018-12-31	GBX-17.90 Million ≈ $-2.18K	GBX-10.08 Million ≈ $-1.23K	0.563x	-29.97%
2017-12-31	GBX-6.55 Million ≈ $-796.70	GBX-5.27 Million ≈ $-640.96	0.805x	+108.26%
2010-12-31	GBX279.19K ≈ $33.97	GBX-2.72 Million ≈ $-330.96	-9.743x	-262.05%
2009-12-31	GBX1.28 Million ≈ $155.48	GBX-3.44 Million ≈ $-418.39	-2.691x	+59.70%
2008-12-31	GBX1.34 Million ≈ $162.71	GBX-8.93 Million ≈ $-1.09K	-6.677x	-508.20%
2007-12-31	GBX10.84 Million ≈ $1.32K	GBX-11.90 Million ≈ $-1.45K	-1.098x	-67.96%
2006-12-31	GBX16.59 Million ≈ $2.02K	GBX-10.84 Million ≈ $-1.32K	-0.654x	-28.61%
2005-12-31	GBX16.50 Million ≈ $2.01K	GBX-8.39 Million ≈ $-1.02K	-0.508x	-274.72%
2003-08-31	GBX-227.62K ≈ $-27.70	GBX-66.20K ≈ $-8.06	0.291x	+264.97%
2002-08-31	GBX-143.28K ≈ $-17.43	GBX25.26K ≈ $3.07	-0.176x	-396.57%
2001-08-31	GBX1.39 Million ≈ $169.63	GBX-49.50K ≈ $-6.02	-0.036x	--

About Ondine Biomedical Inc

LSE:OBI UK Biotechnology

Market Cap

$821.79K

GBX6.75 Billion GBX

Market Cap Rank

#30675 Global

#841 in UK

Share Price

GBX13.00

Change (1 day)

+0.00%

52-Week Range

GBX8.00 - GBX18.00

All Time High

GBX58.50